Akili
Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.
Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.
At CES 2019, the digital therapeutic company's CEO and cofounder described work on an independent prescription, procurement and support platform specific to digital medicines.
The study's 19 young participants stuck to their regimens, and along with their parents said that they would be open to continuing treatment sessions.
Also: Greenway Health appoints new CISO; DocuTAP hires SVP of product, EVP of people and culture.
The new digital therapeutic is being developed at a UCSF, and will join Akili Interactive Labs' pipeline of other video game-based therapeutics.
Boston-based digital therapeutics company Akili Interactive Labs announced this morning that it has added an extra $13 million to its previously announced Series C financing.
A drug no longer needs to be a tangible object, according to panelist at the BIO 2018 convention in Boston.
This morning, Boston-based Akili Interactive Labs announced the closure of a $55 million Series C funding round.